Autologous CD6-CAR regulatory T cells
What it is
A City of Hope pilot plans to test a person’s own regulatory T cells engineered to target CD6. The registry and hospital list it as not yet enrolling; no T1D outcomes are reported.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2026-07-13. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Beta-cell preservation: No clinical preservation result is posted for this programme.[1]
- Important harms and treatment burden
- Safety: The study is designed to assess safety; no programme-specific adverse-event results are posted.[1]
- Approval and country access
- A City of Hope pilot plans to test a person’s own regulatory T cells engineered to target CD6. The registry and hospital list it as not yet enrolling; no T1D outcomes are reported.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Lasting immune control or insulin independence has not been demonstrated in the registry.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 10 × 30 + 8 × 20 + 20 × 20 + 25 × 10 + 15 × 20 = 1410; divide by total weight 100. Unrounded weighted result: 14.1.
Lasting immune control or insulin independence has not been demonstrated in the registry.[1]
The study is designed to assess safety; no programme-specific adverse-event results are posted.[1]
The protocol selects adults 18–35, 12–24 months after diagnosis, with autoantibodies and residual C-peptide.[1]
Evidence is limited to an early registered study; planned enrolment is not a treated or analyzed cohort.[1]
The full picture
What is being proposed
This programme engineers a patient's own regulatory T cells to recognize CD6 on other immune cells. The aim is to reduce the autoimmune attack. Its identity is distinct from unmodified polyclonal Tregs and from CAR-T approaches that deplete immune cells.1
Status and limits
The open-label pilot plans six participants and emphasizes safety, tolerability and feasibility. The registry's estimated September 2026 dates have passed, but it still says not yet recruiting. City of Hope also lists this study under “Coming Soon,” so the dates are not evidence that it started or finished.1 2
No T1D outcomes are posted. The protocol requires willingness for long-term follow-up extending to 15 years; that is a surveillance plan, not evidence of 15-year benefit. An engineered-cell infusion cannot be assumed safe because it uses a person's own cells. The primary unresolved questions are toxicity, persistence and whether residual insulin production changes.
Sources
- [1]NCT07395050 — study record · registry · 2026-07-13 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.
- [2]City of Hope diabetes clinical trials — CD6-CAR Tregs coming soon · news — Investigator institution page, not a peer-reviewed outcomes report.